By standardizing financial instruments and reporting mechanisms, the agency would give regulators a broader view of the health of participants in the financial markets and the potential for problems to spread.
We investigate the feasibility of a model-driven software approach to address this challenge, whereby an improvement model designed by a team is used to automatically generate required electronic data collection instruments and reporting tools.
Differences in survey instruments and reporting formats make it difficult to compare their results to ours directly, but taken together these studies suggest that the improvements we observed are not unique to our study population or the specific outcomes we assessed.
Systematic literature searches were conducted to identify studies that conducted statistical mapping to predict EQ-5D utilities or responses from any source instrument and reported the estimated algorithms in sufficient detail to allow other researchers to use them to predict EQ-5D in other studies.
The instruments used and reported here were EQ-5D™, EORTC QLQ-C30 and EORTC QLQ-CR38.
Therefore, we hope that future studies can provide additional evidence of the validity of the instruments developed and reported herein.
The other 55 trials (85%) used at least one validated instrument (seven trials reported three different instruments and 16 reported two instruments).
No anchor-based values for interpreting change were reported for any of the reviewed instruments, and none reported responder definitions for an epilepsy population according to the FDA's requirements around establishing responder definitions (see Table 1).
While a variety of outcome instruments are used and reported in studies of hip arthroplasty, HHS is the most commonly used instrument in studies of hip arthroplasty [ 2].
Technical advances in the development of field-deployable capillary and microchip electrophoretic instruments and reports of their deployment between 2013 and 2017 were reviewed.
